Marstacimab  (Synonyms: PF-06741086)

Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia^[1][2].

Human IgG1 lambda2

Human IgG1 lambda2, Isotype Control

Human

TFPI

Marstacimab (20, 50 and 100 nmol/L) decreases rotational thromboelastometry (ROTEM) corn trypsin (CT) of the whole blood that obtained from haemophilia participants^[1].
Marstacimab (16 μg/mL) decreases the lag time and increases thrombin generation of human nonhemophilic plateletpoor plasma samples in vitro^[2].
Marstacimab (16 μg/mL) increases the peak thrombin in both hemophilia A and hemophilia B plasma samples in vitro^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Marstacimab (0.5 mg/kg; i.v., once) does not affect the blood flow situation in mouse acute bleeding models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

7035  [NCBI]

P10646

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.98 kDa

1985638-39-8

Liquid

Colorless to light yellow

[Marstacimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda2

• 
  Flow Cytometry analysis of Hela cells labelling TFPI (red) with Marstacimab (anti-TFPI) (HY-P99725). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 lambda2 (HY-P990096). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. Patel-Hett S, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019 Sep;25(5):797-806.  [Content Brief]

  [2]. Pittman DD, et al. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022 Mar 16;6(2):e12679.  [Content Brief]